Patient Disparity in Trials vs Clinic Raises Doubts on Kidney Cancer Drug Efficacy
the ONA take:
Four drugs that were recently approved by the FDA for the treatment of kidney cancer are being doubted for their clinical application based on trial data, according to a recent study published in the Journal of Oncology Practice.
Researchers led by Aaron Mitchell, MD, of the University of North Carolina at Chapel Hill Medical Center, found that with regard to certain cancer drugs, participants in clinical trials are often not representative of patients that ultimately take the drugs.
“We found that patients participating in clinical trials are younger and healthier than many of the patients who are receiving these drugs in the clinical setting,” Mitchell said.
The study compared patients who participated in stage III clinical trials for four kidney cancer drugs with those who received the drugs at both academic and community medical centers.
The researchers found that 39% of the patients who received the drugs would have been considered too sick to participate in the original trials, and therefore would have been excluded.
“If a person will be getting the drug in a clinical setting it is important to know if they can expect to see the same benefits or if they might experience more dangerous side effects,” Mitchell noted.
“Physicians can’t know for sure because the trial data do not directly apply.”
He urged that since current trials are designed by pharmaceutical companies to make them “more expedient,” it may be more realistic to change the perception that FDA approval is the end point for studying a drug efficacy.
Four drugs that were recently approved by the FDA for the treatment of kidney cancer are being doubted for their clinical application.
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- Directly Informing Patients of Breast Cancer Risk, Options Improves Follow-Up Screening
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Free Lung Cancer Screening Findings Support Continual Screenings in High-Risk Populations
- Parental Self-persuasion in Low-Income Groups Improves HPV Vaccination Rates
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Shared Decision-making Visits Improved Comfort With Lung Cancer Screening Decisions
- Temozolomide With Radiotherapy for Glioblastoma Provides Some Survival Benefit in Elderly
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|